Premium
Activation of Rac1 promotes hedgehog‐mediated acquisition of the myofibroblastic phenotype in rat and human hepatic stellate cells
Author(s) -
Choi Steve S.,
Witek Rafal P.,
Yang Liu,
Omenetti Alessia,
Syn WingKin,
Moylan Cynthia A.,
Jung Youngmi,
Karaca Gamze F.,
Teaberry Vanessa S.,
Pereira Thiago A.,
Wang Jiangbo,
Ren XiuRong,
Diehl Anna Mae
Publication year - 2010
Publication title -
hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.488
H-Index - 361
eISSN - 1527-3350
pISSN - 0270-9139
DOI - 10.1002/hep.23649
Subject(s) - rac1 , hepatic stellate cell , microbiology and biotechnology , biology , hedgehog , rac gtp binding proteins , transgene , genetically modified mouse , cytoprotection , cancer research , myofibroblast , signal transduction , apoptosis , pathology , medicine , biochemistry , endocrinology , gene , fibrosis
Hepatic accumulation of myofibroblastic hepatic stellate cells (MF‐HSCs) is pivotal in the pathogenesis of cirrhosis. Two events are necessary for MF‐HSCs to accumulate in damaged livers: transition of resident, quiescent hepatic stellate cells (Q‐HSCs) to MF‐HSCs and expansion of MF‐HSC numbers through increased proliferation and/or reduced apoptosis. In this study, we identified two novel mediators of MF‐HSC accumulation: Ras‐related C3 botulinum toxin substrate 1 (Rac1) and Hedgehog (Hh). It is unclear whether Rac1 and Hh interact to regulate the accumulation of MF‐HSCs. We evaluated the hypothesis that Rac1 promotes activation of the Hh pathway, thereby stimulating signals that promote transition of Q‐HSCs into MF‐HSCs and enhance the viability of MF‐HSCs. Using both in vitro and in vivo model systems, Rac1 activity was manipulated through adenoviral vector‐mediated delivery of constitutively active or dominant‐negative rac1. Rac1‐transgenic mice with targeted myofibroblast expression of a mutated human rac1 transgene that produces constitutively active Rac1 were also examined. Results in all models demonstrated that activating Rac1 in HSC enhanced Hh signaling, promoted acquisition/maintenance of the MF‐HSC phenotype, increased MF‐HSC viability, and exacerbated fibrogenesis. Conversely, inhibiting Rac1 with dominant‐negative rac1 reversed these effects in all systems examined. Pharmacologic manipulation of Hh signaling demonstrated that profibrogenic actions of Rac1 were mediated by its ability to activate Hh pathway‐dependent mechanisms that stimulated myofibroblastic transition of HSCs and enhanced MF‐HSC viability. Conclusion : These findings demonstrate that interactions between Rac1 and the Hh pathway control the size of MF‐HSC populations and have important implications for the pathogenesis of cirrhosis. H EPATOLOGY 2010